Successful clinical trials of Opioid Growth Factor (OGF) have been carried out in:

• • Pancreatic cancer
• • Lung cancer
• • AIDS
• • Multiple Sclerosis
• • Behcet’s Disease
• • Optic neuritis
• • Uveitis

The following cancers have been shown to have OGF receptors and may be candidates for the use of OGF or OGF-boosting mechanisms:

• • Breast Cancer
• • Cervical Cancer
• • Colon and Rectal Cancer
• • Gastric Cancer
• • Glioblastoma
• • Head and Neck
• • Kaposi’s Sarcoma
• • Leukemia – Lymphocytic
• • Liver Cancer • Lymphoma – B Cell and T Cell
• • Malignant Melanoma
• • Neuroblastoma
• • Ovarian Cancer
• • Prostate Cancer
• • Renal Cell Carcinoma
• • Small Cell and Non-Small Cell Lung Cancer
• • Throat Cancer
• • Tongue Cancer
• • Uterine Cancer

Opioid Growth Factor is not yet FDA-approved for these conditions. However, it has been used by physicians worldwide over the past 20 years, primarily in treating cancer. For this use, it has been prepared by compounding pharmacies.

In the interests of promoting further research into different uses of OGF, we encourage OGF users who are willing to be identified to post their experiences with OGF here.

Examples of the successful use of OGF, reported by patients to date, include the following conditions:

• - Pancreatic Cancer
• - Hepatoblastoma
• - Breast Cancer
• - Ovarian Cancer
• - Lung Cancer (NSCLC)